Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma

Copyright © 2020 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved..

Sonidegib is an antagonist of the transmembrane protein Smoothened in the Hedgehog signaling pathway. It is indicated for the treatment of locally advanced basal cell carcinoma (BCC) that is not amenable to curative surgery or radiotherapy. Sonidegib's efficacy and safety were demonstrated in the phase 2 BOLT trial, where 61% (95% CI, 48-72%) of patients with locally advanced BCC treated with sonidegib 200 mg achieved an objective response to treatment with a mean time to response of 4 months. The median duration of response was 26.1 months and the median progression-free survival was 22.1 months. The most common adverse events were muscle spasms (54.4%), hair loss (49.4%), and loss of taste (44.3%); most events were grade 1 or 2. In this review, we summarize the main findings on the efficacy, safety, and tolerability of sonidegib and discuss the management of locally advanced BCC with this drug.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:112

Enthalten in:

Actas dermo-sifiliograficas - 112(2021), 4 vom: 15. Apr., Seite 295-301

Sprache:

Englisch

Weiterer Titel:

Sonidegib en el tratamiento del carcinoma basocelular localmente avanzado

Beteiligte Personen:

Sanmartín, O [VerfasserIn]
Llombart, B [VerfasserIn]
Carretero Hernández, G [VerfasserIn]
Flórez Menéndez, Á [VerfasserIn]
Botella-Estrada, R [VerfasserIn]
Herrera Ceballos, E [VerfasserIn]
Puig, S [VerfasserIn]

Links:

Volltext

Themen:

0RLU3VTK5M
Antineoplastic Agents
Biphenyl Compounds
Carcinoma basocelular localmente avanzado
Hedgehog Proteins
Hedgehog pathway inhibitors
Hedgehog signaling pathway
Inhibidores de la vía Hedgehog
Journal Article
Locally advanced basal cell carcinoma
Pyridines
Review
Sonidegib
Vía de señalización Hedgehog

Anmerkungen:

Date Completed 24.06.2021

Date Revised 24.06.2021

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.ad.2020.11.002

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM317648195